Abstract
The XIENCE family of everolimus-eluting stents ranks among the most used and most widely studied drug-eluting stents worldwide. In patients at high bleeding risk undergoing non-complex percutaneous coronary intervention with these stents, a shortened dual antiplatelet therapy (DAPT) regimen of 1–3 months appears to be associated with a reduced rate of major bleeding, a similar rate of ischaemic events and a very low incidence of stent thrombosis after DAPT discontinuation compared with DAPT up to 12 months.
Original language | English |
---|---|
Pages (from-to) | 1-2 |
Number of pages | 2 |
Journal | Heart International |
Volume | 15 |
Issue number | 2 |
State | Published - 2021 |
Externally published | Yes |
Keywords
- Aspirin
- Drug-eluting stents
- Dual anti-platelet therapy
- High bleeding risk
- P2Y12 inhibitor
- Percutaneous coronary intervention
- XIENCE stent